Melissa Bersanelli

32PUBLICATIONS
195CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumoursPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Apr 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.

Sebastiano Buti, Alessandro Olivari, Cristina Masini

|Oct 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.

Khalil Choucair, Caroline Nebhan, Alessio Cortellini

|Sep 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.

Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato

|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Talal El Zarif, Amin H Nassar, Elio Adib

|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.

Satoru Taguchi, Taketo Kawai, Sebastiano Buti

|May 01, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.

Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary

Pageof 6

Frequent Collaborators

19 joint publications

Sebastiano Buti

6 joint publications

Alessio Cortellini

5 joint publications

Carlo Cattrini

3 joint publications

David J Pinato